<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888598</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-RET-2020-69</org_study_id>
    <nct_id>NCT04888598</nct_id>
  </id_info>
  <brief_title>Microvascular Changes in OCT-angiography in Type 1 Diabetes Mellitus at the Onset of the Disease and After Optimization of Glycemic Control.</brief_title>
  <official_title>Study of the Microvascular Changes in the Retina Measured by Optical Coherence Tomography (OCT) - Angiography in Patients With Type 1 Diabetes Mellitus at the Onset of the Disease and After Optimization of Glycemic Control.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundaci처 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Arnau de Vilanova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundaci처 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the differences in the retinal microcirculation&#xD;
      measured by OCT-Angiography in patients with type 1 diabetes between the diagnosis of the&#xD;
      disease and after 3 months of insulin treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vessel density</measure>
    <time_frame>3 months</time_frame>
    <description>Density of retinal vessels and perfusion in the macula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vessel density</measure>
    <time_frame>6 months</time_frame>
    <description>Density of retinal vessels and perfusion in the macula</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Type 1 diabetic patients</arm_group_label>
    <description>Recently diagnosed type 1 diabetes patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography (OCT) Angiography</intervention_name>
    <description>Measurement of retinal vessel density and distribution in the macula using new generation OCT device</description>
    <arm_group_label>Type 1 diabetic patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with type 1 diabetes who meet all the inclusion criteria and none of the&#xD;
        exclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Type 1 Diabetes at diagnosis of the disease (less than 7 days after&#xD;
             diagnosis)&#xD;
&#xD;
          -  Age equal to or greater than 18 years&#xD;
&#xD;
          -  Signature of the informed consent by the patient / legal guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metabolic situation of ketosis or ketoacidosis, according to clinical criteria&#xD;
             established in the protocol of the Endocrinology and Nutrition Service. The patient&#xD;
             will be a candidate once the ketonemia is absent (value &lt;1 mmol / L).&#xD;
&#xD;
          -  Previous diagnosis of dyslipidemia and any previous lipid-lowering treatment&#xD;
&#xD;
          -  Previous diagnosis of hypertension and any previous hypotensive treatment&#xD;
&#xD;
          -  Previous diagnosis of any form of cardiovascular disease, including heart failure.&#xD;
&#xD;
          -  Previous kidney disease, and presence of advanced kidney failure (estimated glomerular&#xD;
             filtration rate &lt;60 ml / min)&#xD;
&#xD;
          -  Presence of diabetic retinopathy identifiable by conventional eye fundus or&#xD;
             retinography, or other concomitant retinal vascular pathology (hypertensive&#xD;
             retinopathy, venous occlusion, arterial obstruction, etc.)&#xD;
&#xD;
          -  History or presence of retinal pathology that may alter its structure and / or the&#xD;
             validity of the measurements (retinal detachment, epiretinal membrane, high myopia&#xD;
             -understood as an axial length greater than or equal to 26mm measured by &quot;IOL Master&quot;&#xD;
             biometry-, neovascular membrane, choroidal tumors, etc.)&#xD;
&#xD;
          -  History of posterior uveitis or retinal vasculitis&#xD;
&#xD;
          -  Glaucoma and neuro-ophthalmological pathology that can alter the neuroretinal&#xD;
             structures.&#xD;
&#xD;
          -  Refractive media opacity that prevents a correct acquisition of images and, therefore,&#xD;
             their evaluation&#xD;
&#xD;
          -  Dementia or intellectual disability that prevent proper collaboration when acquiring&#xD;
             images&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Salvador, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundaci처 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Salvador, MD</last_name>
    <phone>+34 93 553 74 90</phone>
    <email>isalvador@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Salvador, MD</last_name>
      <phone>93 553 74 90</phone>
      <email>isalvador@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Traveset, PhD</last_name>
      <phone>+34 973 248100</phone>
      <email>sjimenez.lleida.ics@gencat.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64. doi: 10.2337/dc11-1909. Epub 2012 Feb 1. Review.</citation>
    <PMID>22301125</PMID>
  </reference>
  <reference>
    <citation>Garg S, Davis R. Diabetic Retinopathy Screening Update. Clinical Diabetes. 2009;27(4):140-145. doi:10.2337/diaclin.27.4.140</citation>
  </reference>
  <reference>
    <citation>van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, Kofinis A, Rottiers R, Porta M, Chaturvedi N; EURODIAB prospective complications study. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care. 2005 Jun;28(6):1383-9.</citation>
    <PMID>15920056</PMID>
  </reference>
  <reference>
    <citation>Rodrigues TM, Marques JP, Soares M, Sim찾o S, Melo P, Martins A, Figueira J, Murta JN, Silva R. Macular OCT-angiography parameters to predict the clinical stage of nonproliferative diabetic retinopathy: an exploratory analysis. Eye (Lond). 2019 Aug;33(8):1240-1247. doi: 10.1038/s41433-019-0401-7. Epub 2019 Mar 22.</citation>
    <PMID>30903092</PMID>
  </reference>
  <reference>
    <citation>Dimitrova G, Chihara E, Takahashi H, Amano H, Okazaki K. Quantitative Retinal Optical Coherence Tomography Angiography in Patients With Diabetes Without Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):190-196. doi: 10.1167/iovs.16-20531.</citation>
    <PMID>28114579</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCT-A</keyword>
  <keyword>OCT Angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

